Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

- PMLiVE

Cervical Cancer Prevention Month

In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer

Innovative Trials

- PMLiVE

Meet Innovative Trials at SCOPE 2022

Stop by Booth 1015 to meet the Innovative Trials' team during SCOPE 2022

Innovative Trials

The New Normal: Upcoming Trends in Clinical Trials

Samuel Searcy, Founder & CEO of CliniStart, shares his expert insights into trends, current gaps, and future predictions for clinical trials. Among many other things, we also dive into his...

Impetus Digital

- PMLiVE

BMS and Century Therapeutics agree on deal potentially worth over $3bn

The collaboration unites Century’s iPSC-derived allogeneic cell therapy line with BMS’s record in developing oncology drugs and cell therapies

- PMLiVE

Amgen’s Lumykras receives conditional marketing authorisation from EC

The drug is the first targeted therapy for patients diagnosed with advanced NSCLC with the KRAS G12C mutation

- PMLiVE

J&J’s COVID-19 booster shows 85% effectiveness in preventing hospitalisation for COVID-19 in study

The Sisonke study was done in South Africa while Omicron was the dominant variant

Innovation in Research, Digital Solutions and Patient Engagement

Craig Lipset, Founder and Advisor at Clinical Innovation Partners and former Head of Clinical Innovation and Venture Partner at Pfizer, talks about everything from his personal health journey to his...

Impetus Digital

- PMLiVE

Tezspire approved in US for severe asthma

AstraZeneca and Amgen’s monoclonal antibody Tezspire is now available to control dangerous exacerbations in all adults and children aged 12 years and above with severe asthma

- PMLiVE

US prefers mRNA COVID-19 vaccines over J&J

Citing concerns over blood clots, Americans are now advised that should get the Pfizer-BioNTech or Moderna vaccines in preference to Johnson and Johnson vaccine

- PMLiVE

FDA approves first drug to prevent graft-versus-host disease

Bristol Myers Squibb’s arthritis drug, Orencia, can now be given to adults and children undergoing stem cell transplants to prevent the life-threatening condition

- PMLiVE

Interview with Kate Shaw, Innovative Trials’ Founder/CEO

2021 has been a very busy year for Innovative Trials and Kate Shaw discusses the main highlights.

Innovative Trials

Amplifying Data Science Tools for End-to-End eClinical Solutions

Andreas Weber, Group CEO, EvidentIQ, discusses hybrid vs. fully decentralized trials, the use of real-world evidence (RWE) in clinical trials, and how an end-to-end eClinical solution can help meet increasing...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links